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Abstract
Background: Typhoid and paratyphoid fever are endemic in China. The objective of this investigation was to
determine the molecular features of nalidixic acid-resistant Salmonella enteric serovar Typhi (S. typhi) and Paratyphi
(S. paratyphi) from blood isolates in Shenzhen, China.
Results: Twenty-five S. typhi and 66 S. paratyphi were isolated from 91 bacteriemic patients between 2002 and
2007 at a hospital in Shenzhen, Southern China. Fifty-two percent (13/25) of S. typhi and 95.3% (61/64) of S.
paratyphi A were resistant to nalidixic acid. Sixty-seven isolates of nalidixic acid-resistant Salmonella (NARS) showed
decreased susceptibility to ciprofloxacin (MICs of 0.125-1 μg/mL). All 75 NARS isolates had a single substitution in
the quinolone resistance-determining region (QRDR) of GyrA (Ser83®Phe/Pro/Tyr, or Asp87®Gly/Asn), and 90.7%
of these isolates carried the substitution Ser83Phe in GyrA. No mutation was found in the QRDR of gyrB, parC,o r
parE. Plasmid mediated quinolone resistance genes including qnr and aac(6’)-Ib-cr were not detected in any isolate.
Twenty-two distinct pulsed field gel electrophoresis (PFGE) patterns were observed among S. typhi. Sixty-four
isolates of S. paratyphi A belonged to one clone. Eighty-seven investigated inpatients were infected in the
community. Six patients infected by S. paratyphi A had a travel history before infection.
Conclusions: Nalidixic acid-resistant S. typhi and S. paratyphi A blood isolates were highly prevalent in Shenzhen,
China. PFGE showed the variable genetic diversity of nalidixic acid-resistant S. typhi and limited genetic diversity of
nalidixic acid -resistant S. paratyphi A.
Background
Typhoid and paratyphoid fever, due to infection with
Salmonella enteric serovar Typhi (S. typhi)a n dP a r a t y -
phi (S. paratyphi), are major global problems. Nalidixic
acid-resistant (NAR) S. typhi and S. paratyphi are ende-
mic to many Asian countries [1]. NAR isolates have
reduced susceptibility to fluoroquinolones, which is
associated with higher rates of morbidity and mortality,
particularly prolonged fever clearance time and
increased need for retreatment [2]. Quinolone resistance
in Salmonella is usually associated with mutations of
the target site, DNA gyrase, most commonly in the qui-
nolone resistance-determining region (QRDR) of the A
subunit. Plasmid mediated quinolone resistance genes of
qnr (qnrA, qnrB, qnrS, and qnrD) and aac(6’)-Ib-cr has
also been described in quinolone-resistant non-Typhi
Salmonella[3,4]. In China, the molecular characterization
and antimicrobial susceptibility of non-Typhi serotypes
of Salmonella enterica have been recently reported [4],
however the molecular mechanism of resistance and
epidemiology of NAR S. typhi and S. paratyphi is not
available. In this study we investigated the molecular
basis of resistance and the epidemiology of 25 S. typhi
and 66 S. paratyphi blood isolates that were recovered
from hospitalized patients in Shenzhen City, Southern
China over 6-year period. The cases were retrospectively
examined for epidemiologic analysis.
Methods
The study site was the Shenzhen People’s Hospital, a
1090-bed medical center for patients who reside in
Shenzhen, Guangdong Province of Southern China, with
an estimated population of 12 million people. This
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Bacterial isolates and susceptibility testing
Ninety-one non-duplicate isolates of Salmonella (25
S. typhi,6 4S. paratyphi A, 1 S. paratyphi B, and 1 S.
paratyphi C) were consecutively obtained from blood
cultures of 91 patients with typhoid or paratyphoid from
2002 through 2007 (2002, n = 13; 2003, n = 27; 2004, n
= 21; 2005, n = 6; 2006, n = 15; 2007, n = 9). All isolates
were identified with standard biochemical tests and spe-
cific antisera (Institute of Biological Products, Lanzhou,
China). The MICs of nalidixic acid and the other anti-
microbial agents were determined by agar dilution
method according to Clinical and Laboratory Standard
Institute (CLSI) M7-A7 [5] and were interpreted accord-
ing to CLSI performance standard M100-S17 [6]. The
antimicrobials were supplied and stored according to
the manufacturer’s instructions. Escherichia coli ATCC
25922 and Pseudomonas aeruginosa ATCC 27853 were
used as quality control strains for susceptibility testing.
Multidrug-resistant strains were defined as those resis-
tant to ampicillin, chloramphenicol, and trimethoprim/
sulfamethoxazole (TMP-SMZ) [7].
Polymerase chain reaction (PCR) and DNA sequencing
All 91 isolates were screened for the qnr (qnrA, qnrB,
and qnrS) genes by multiplex PCR [8] and for aac(6’)-Ib
by PCR [9]. PCR amplification of the quinolone resis-
tance-determining regions (QRDRs) of gyrA, gyrB, parC,
and parE was performed in all isolates as described pre-
viously [10]. Mutations in the gyrA, gyrB, parC,a n d
parE genes were identified by DNA sequencing. The
PCR products were purified by using a QIAquick PCR
purification kit (Qiagen, Hilden, Germany). DNA
sequencing of both strands was performed by the direct
sequencing method with an ABI Prism 3100 generic
analyzer (Applied Biosystems, Foster City, CA), and the
DNA sequences of the QRDRs of gyrA, gyrB, parC,a n d
parE were compared with the DNA sequences of the
QRDRs of S. typhi, S. paratyphi A, and S. paratyphi B
(GenBank: NC_004631, NC_006511, NC_010102). b-lac-
tamase genes were detected by PCR with primers speci-
fic for blaCTX-M, blaTEM, blaSHV, blaOXA among isolates
resistant to ampicillin as described previously [11-13],
and PCR products were sequenced as described above.
Class 1 intergron as was investigated by PCR. PCR pro-
ducts were sequenced using a pair of specific primers of
5’CS and 3’CS for multidrug-resistant isolates [14].
Pulsed field gel electrophoresis
PFGE of XbaI (New England)-digested genomic DNA of
all isolates was carried out using the CHEF MAPPER
system (Bio-Rad), as described by the standard PulseNet
protocol for Salmonella species by the Centers for Dis-
ease Control and Prevention [15]. Similarities among
macrorestriction patterns were determined both by
visual comparison and computer matching with BioNu-
merics 4.0 software. Dendrograms for similarity were
built using the unweighted-pair group method using
arithmetic averages. Patterns differing by zero to three
fragments are considered to belong to the same PFGE
type according to the method of Tenover et al [16].
Case investigation
A case was defined as illness compatible with acute
typhoid or paratyphoid fever and isolation of S. typhi or
S. paratyphi from a sterile site. A total of 87 cases of
acute S. typhi and S. paratyphi A infections were retro-
spectively examined over a 6-year period; the medical
records from 2 outpatients infected by S. paratyphi A
were unavailable. Demographic, epidemiologic, and clin-
ical information were recorded on case report forms
that included age, sex, habitation, history of travel in the
30 days preceding illness onset, clinical symptoms and
signs, laboratory data, and antimicrobial therapy. We
did not include data about previous immunization
against typhoid fever because it was unavailable for
most of patients. Statistical analysis was performed
using SPSS for Windows (release 13.0).
Results
Antimicrobials susceptibility
Fifty-two percent (13/25) of S. typhi and 95.3% (61/64)
of S. paratyphi A were resistant to nalidixic acid, respec-
tively (table 1). More than half of nalidixic acid-resistant
S. paratyphi A isolates were detected between 2003 and
2004 (table 2). Sixty-seven isolates of nalidixic acid-resis-
tant Salmonella (including 6 S. typhi,6 0S. paratyphi A
and 1 S. paratyphi C) showed decreased susceptibility to
ciprofloxacin (MIC = 0.125-1 μg/mL), although all were
susceptible to the fluoroquinolones according to current
CLSI breakpoints.
Twenty-five S. typhi and 64 S. paratyphi A were highly
susceptible to ampicillin, chloramphenicol and TMP-
SMZ, with the overall susceptibility being 96%~100%
(table 1). Resistance to ceftriaxone and cefotaxime was
detected only in 1 isolate of S. paratyphi A( M I C=6 4
μg/mL). Interestingly, only one S. typhi showed resistance
to ampicillin (MIC ≥ 256 μg/mL). One isolate of S. para-
typhi B was susceptible to all drugs tested and one isolate
of S. paratyphi C showed multiple resistance to nalidixic
acid (MIC ≥ 256 μg/mL), ampicillin (MIC ≥ 256 μg/mL),
chloramphenicol (MIC ≥ 256 μg/mL), and TMP-SMZ
(MIC ≥ 32 μg/mL).
PCR and DNA sequencing
All 75 NARS had a single point mutation in the QRDR
of gyrA that led to a single-amino-acid substitution at
codons 83 or 87 of GyrA (Ser83®Phe, Ser83®Pro,
Ser83®Tyr, Asp87®Gly, or Asp87®Asn) (table 3), and
90.7% (68/75) of these isolates carried the substitution
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QRDR of gyrB, parC,o rparE. For all 16 NASS isolates,
no point mutation was detected in the QRDR of gyrA/B
or parC/E gene. Plasmid-mediated quinolone resistance
genes including qnr and aac(6’)-Ib-cr were not detected
in any isolate. The blaCTX-M-14 gene was detected in the
ceftriaxone-resistant isolate of S. paratyphi A, with
ISEcp1 located on the upstream of blaCTX-M-14 gene. A
1.9-kb class 1 integron gene cassette dhfrXII-orfF-aadA2
was identified in the multidrug-resistant isolate of S.
paratyphi C, in which blaTEM-1 gene was also detected.
None of blaCTX-M, blaTEM, blaSHV and blaOXA genes
were identified in the ampicillin-resistant isolate of
S. typhi.
PFGE
Overall, 22 different PFGE patterns were observed
among 25 isolates of S. typhi from 2002 through 2007
(figure 1); 10 of 22 PFGE patterns were identified
among 13 nalidixic acid-resistant isolates. The variable
genetic diversity among S. typhi isolates suggested ende-
mic disease from multiple sources. In contrast, among
64 isolates of S. paratyphi A, 41 isolates (including 39
NARS) were assigned to PFGE type A (figure 2 and 3),
21 isolates (including 20 nalidixic acid-resistant isolates)
belonging to subtype A1 (difference by one band of
~310 kb compared to type A), and 2 nalidixic acid-resis-
tant isolates to subtype A2 (difference by one band of
~310 kb and one band of ~190 kb compared to type A).
The limited genetic diversity (similarity coefficient of
91%) among S. paratyphi A isolates indicated endemic
disease from the presence of a single clone over 6-year
period.
Case investigation
Infection was acquired in community in 87 patients. All
patients were residents of Shenzhen City, and were
mostly young or middle age and lived in sanitary envir-
onments. Six patients infected by S. paratyphi Ah a d
traveled to other cities or regions in the 30 days preced-
ing illness onset, including Shaoguan City in Southern
China (n = 1), Chongqing City and Guizhou province in
S o u t h w e s t e r nC h i n a( n=3 ) ,T a i w a n( n=1 ) ,a n dB a n -
gladesh (n = 1). More than 80% of patients (20 S. typhi-
infected patients and 52 S. paratyphi A-infected
patients, respectively) had received antimicrobials prior
to hospital admission. They were primarily hospitalized
due to fever for at least 3 days.
Epidemiological, clinical and laboratory features are
presented in table 4. Clinical treatment and outcome in
23 nalidixic acid-susceptible Salmonella (NASS) and
nalidixic acid-resistant Salmonella (NARS)-infected
Table 1 Susceptibilities of S. typhi and S. paratyphi A to 12 antimicrobial agents
Antimicrobial agents S. typhi (N = 25) S. paratyphi A (N = 64)
R% S% MIC50
(μg/mL)
MIC90
(μg/mL)
R% S% MIC50
(μg/mL)
MIC90
(μg/mL)
Nalidixic acid 52 48 64 ≥256 95.3 4.7 ≥256 ≥256
Norfloxacin 0 100 0.25 1 0 100 2 2
Ciprofloxacin 0 100 0.064 0.25 0 100 0.5 0.5
Levofloxacin 0 100 0.125 0.5 0 100 1 1
Gatifloxacin 0 100 0.064 0.25 0 100 0.5 1
Sparfloxacin* - - 0.125 1 - - 1 2
Moxifloxacin* - - 0.125 0.5 - - 1 1
Cefotaxime 0 100 0.064 0.064 1.6 98.4 0.125 0.5
Ceftriaxone 0 100 0.064 0.125 1.6 98.4 0.125 0.25
Ampicillin 4 96 1 4 1.6 98.4 2 4
Chloramphenicol 0 100 2 4 0 98.4 4 8
Trimethoprim/sulfamethoxazole 0 100 0.25 0.25 0 100 0.25 0.25
* CLSI had no breakpoints for these agents
R - Resistant
S - Susceptible
Table 2 Isolates of NARS collected during 2002 to 2007
Microorganism 2002 2003 2004 2005 2006 2007
S. typhi 5 (7)* 2 (7) 1 (3) 1 (1) 1 (3) 3 (4)
S. paratyphi A 5 (6) 19 (19) 16 (18) 4 (4) 12 (12) 5 (5)
S. paratyphi B 0 (0) 0 (1) 0 (0) 0 (0) 0 (0) 0 (0)
S. paratyphi C 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
* parentheses referring to the total number of isolates collected annually for each species
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in table 5. The mean fever clearance time for 6 patients
infected by NASS and 17 patients infected by NARS
were 75.5 hours and 119.2 hours, respectively,
p = 0.178. The illness of the patients infected by cef-
triaxone-resistant S. paratyphi A improved after being
treated with ciprofloxacin (0.4 g IV q12h) for 11 days.
When ceftriaxone was combined with TMP-SMZ
(0.96 g PO q12h) this was shortened to 6 days during
hospitalization; home therapy continued with oral
antimicrobials.
Discussion
Nalidixic acid-resistant S. typhi and S. paratyphi are
endemic in Vietnam and some other South Asia coun-
tries such as India, Pakistan, Bangladesh, and Nepal
[17], with a resistance rate range of 38-97%. It has been
reported that more than 70% of Salmonella enteric sero-
var Typhimurium isolates are resistant to ciprofloxacin
and some have become multidrug-resistant in regions of
C h i n a[ 4 ] .I nt h i ss t u d y ,5 2 %o fS. typhi and 95% of S.
paratyphi A showed resistance to nalidixic acid,
although they were still susceptible to ciprofloxacin
according to the present CLSI breakpoints. Multidrug-
resistant isolates were not detected among S. typhi and
S. paratyphi A in our investigation. Interestingly, 90.7%
of these nalidixic resistant-isolates carried the same gyrA
mutation, leading to the substitution Ser83Phe, which
was identical to that described in Vietnam in 2007 [18].
Importantly, the incidence of S. paratyphi Ai n f e c t i o n
has surpassed that of S. typhi infection since 2003 in
this study. The similar results had been reported in
Guangxi Autonomous Region, China [19], reinforcing
our results. A disproportionate increase in the incidence
of enteric fever caused by S. paratyphi A has also been
Table 3 The point mutation in the QRDR of gyrA of
nalidixic acid-resistant Salmonella.
Point mutation in the QRDR
of gyrA
MIC (μg/mL)*
nalidixic
acid
ciprofloxacin
nalidixic acid-resistant S. typhi
Ser83®Phe (TCC®TTC) ≥ 256 (9) 0.06 (4), 0.125 (1), 0.25
(2), 0.5 (2)
Asp87®Gly (GAC®GGC) 128 (1) 0.06 (1)
Asp87®Asn (GAC®AAC) 64 (2), ≥ 256
(1)
0.06 (2), 0.25 (1)
nalidixic acid-resistant S.
paratyphi A
Ser83®Phe (TCC®TTC) ≥ 256 (59) 0.25 (8), 0.5 (50), 1 (1)
Ser83®Pro (TCC®CCC) 32 (2) 0.125 (1), 0.03 (1)
nalidixic acid-resistant S.
paratyphi C
Ser83®Tyr (TCC®TAC) ≥ 256 (1) 0.125 (1)
* parentheses referring to the number of isolates with the point mutation in
the QRDR of gyrA
Figure 1 Dendrogram for the S. typhi isolates with distinct PFGE types. Genetic similarity was calculated by the Dice coefficients. R,
Resistant; S, Susceptible.
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Thailand [20]. A report from the United States con-
firmed that paratyphoid fever most often was caused by
nalidixic acid-resistant S. paratyphi A, and like typhoid
fever, was usually acquired while traveling internation-
ally. In this observation, infection with S. paratyphi A
was associated with travel to South and Southeast Asia,
and nalidixic acid-resistant infection was associated with
travel to South Asia [20].
PFGE is currently the method for the subtyping of
sporadic or epidemic Salmonella isolates. By the use of
a standardized PFGE protocol in this study, the Pulse-
Net protocol, all isolates of S. paratyphi A were assigned
to type A, subtype A1 or A2, which suggests endemic
disease from the presence of a single clone over 6-year
period. By investigating 62 medical records of inpatients
infected by S. paratyphi A, it was confirmed that five
patients infected by S. paratyphi A had traveled to other
domestic cities or regions, and one had traveled interna-
tionally to Bangladesh. Our data also suggests that the
same clone of S. paratyphi A was present in China over
the study period.
Figure 2 Dendrogram for the S. paratyphi A isolates with the same PFGE types. Genetic similarity was calculated by the Dice coefficients.
R, Resistant; S, Susceptible.
Figure 3 Analysis of S. paratyphi Ai s o l a t e sb yP F G Eo fXbaI
restriction digests. H standard strain H9812; isolates 44, 45, 48-54
(PFGE type A); isolates 43, 46 (PFGE type A1); isolates 47 and 55
(PFGE type A2).
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paratyphi A in New Delhi, India was investigated by
PFGE [21]. The five sporadic isolates of S. paratyphi A
gave PFGE patterns following XbaI digestion that were
distinct, with differences of 8 to 12 bands. In contrast,
the 13 outbreak isolates shared only four closely related
PFGE patterns differing only in 1 to 6 bands. Similar
results were obtained after digestion with a second
restriction endonuclease, SpeI. In another study, a total
of 39 human isolates of S. paratyphi Af r o mP a k i s t a n ,
India, Indonesia and Malaysia were typed by PFGE
using XbaI restriction digests. This study suggested that
a limited number of clones were responsible for paraty-
phoid fever in those countries [22]. Similarly, the high
proportion of S. paratyphi Ai n f e c t i o ni nN e p a ld u r i n g
2001 was due to the emergence of a single clone [23].
In a recent report by Gupta et al [20], 110 isolates of S.
paratyphi A were typed by PFGE of XbaIa n dBlnI
restriction digests, which were obtained from patients
with paratyphoid fever in the United States from 2005
to 2006. Thirty-one molecular subtypes (unique combi-
nations of XbaIa n dBlnI patterns) were identified, and
six subtypes (19%) accounted for 90 (82%) of these
isolates.
Conclusions
Nalidixic acid-resistant S. typhi and S. paratyphi A
blood isolates were highly prevalent in Shenzhen, China.
Table 4 Epidemiological, clinical and laboratory features in the 87 inpatients with culture-confirmed enteric fever
Parameter
a S. typhi-infected patients
(n = 25)
S. paratyphi A-infected patients (n = 62)
Mean age (yr) (range) 26.7 (0-67) 32.7 (16-62)
Male 14 (56) 36 (58)
Previous enteric fever 0 (0) 1 (2)
Contact with patients with enteric fever 0 (0) 1 (2)
Insalubrity intake 3 (12) 1 (2)
Sanitary latrine 25 (100) 61 (98)
History of travel in the 30 days preceding illness onset 0 (0) 6 (10)
Symptoms
Fever 25 (100) 61 (98)
Headache 9 (36) 31 (50)
Chills 18 (72) 45 (73)
Rigor 5 (20) 15 (24)
Sweating 4 (16) 9 (15)
Cough 3 (12) 13 (21)
Abdominal pain 3 (12) 7 (11)
Nausea 3 (12) 10 (16)
Vomiting 2 (8) 8 (13)
Diarrhea 2 (8) 12 (19)
Myalgia 6 (24) 11 (18)
Weight loss 8 (32) 9 (15)
Erythra 3 (12) 3 (5)
Physical finding
Abdominal tenderness 2 (8) 7 (11)
Hepatomegaly 3 (12) 11 (18)
Splenomegaly 7 (28) 30 (48)
Laboratory finding
Mean WBC count (× 10
9/L) (range) 5.6 (2.1-8.5) 5.4 (1.0-16.8)
positive Widal test 16 (84)
b 9 (16)
c
ALT (> 40 IU/L)
d 18 (72) 46 (74)
AST (> 45 IU/L)
e 17 (68) 45 (73)
Complications
f 6 (24) 13 (21)
a Data are presented as no. (%).
b Only 19 patients were detected.
c Only 55 patients were detected.
d AST, aspartate transaminase (normal range, 0-40 IU/L).
e ALT, alanine transaminase (normal range, 0-45 IU/L).
f including toxic hepatitis, toxic myocarditis, intestinal hemorrhage, bronchitis, pneumonia, and bacterial meningitis.
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acid-resistant S. typhi and limited genetic diversity of
nalidixic acid-resistant S. paratyphi At h a ts u g g e s t sa
clonal expansion of S. paratyphi A infection in the
community.
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Table 5 Clinical treatments and outcomes in nalidixic acid-susceptible Salmonella (NASS) and nalidixic acid-resistant
Salmonella (NARS)-infected patients treated with fluoroquinolones only
a
Antimicrobial agents NASS-infected patients (n = 6) NARS-infected patients (n = 17)
Dosage Number Duration (d) Number Duration (d)
Ciprofloxacin 0.4 g IV q12h 5 7~13 8 7~21
0.2 g IV q12h 1 5 2 10~15
Levofloxacin 0.3 g IV q12h - - 1 7
0.2 g IV q12h - - 2 7~8
Gatifloxacin 0.2 g IV q12h - - 3 10~14
0.4 g IV q24h - - 1 13
aAll of these 23 patients treated with fluoroquinolones only were cured.
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